25 XP   0   0   10

Nephros Inc
Buy, Hold or Sell?

Let's analyse Nephros together

PenkeI guess you are interested in Nephros Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Nephros Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Nephros Inc

I send you an email if I find something interesting about Nephros Inc.

Quick analysis of Nephros (30 sec.)










What can you expect buying and holding a share of Nephros? (30 sec.)

How much money do you get?

How much money do you get?
$0.01
When do you have the money?
1 year
How often do you get paid?
15.0%

What is your share worth?

Current worth
$0.79
Expected worth in 1 year
$0.74
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
$-0.04
Return On Investment
-2.1%

For what price can you sell your share?

Current Price per Share
$2.03
Expected price per share
$1.4701 - $2.06
How sure are you?
50%

1. Valuation of Nephros (5 min.)




Live pricePrice per Share (EOD)

$2.03

Intrinsic Value Per Share

$-1.31 - $5.33

Total Value Per Share

$-0.51 - $6.12

2. Growth of Nephros (5 min.)




Is Nephros growing?

Current yearPrevious yearGrowGrow %
How rich?$8.3m$11m-$2.4m-28.4%

How much money is Nephros making?

Current yearPrevious yearGrowGrow %
Making money-$394k-$1.8m$1.4m364.7%
Net Profit Margin-11.4%-75.6%--

How much money comes from the company's main activities?

3. Financial Health of Nephros (5 min.)




4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)




  Industry Rankings (Medical Instruments & Supplies)  


Richest
#142 / 171

Most Revenue
#139 / 171

Most Profit
#109 / 171

Most Efficient
#125 / 171

What can you expect buying and holding a share of Nephros? (5 min.)

Welcome investor! Nephros's management wants to use your money to grow the business. In return you get a share of Nephros.

What can you expect buying and holding a share of Nephros?

First you should know what it really means to hold a share of Nephros. And how you can make/lose money.

Speculation

The Price per Share of Nephros is $2.03. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nephros.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nephros, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.79. Based on the TTM, the Book Value Change Per Share is $-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.14 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nephros.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.06-3.1%-0.04-2.0%-0.18-8.6%-0.10-5.0%-0.09-4.6%
Usd Book Value Change Per Share-0.03-1.2%-0.01-0.6%-0.14-6.9%0.010.4%0.021.0%
Usd Dividend Per Share0.000.0%0.000.1%0.000.2%0.000.1%0.041.9%
Usd Total Gains Per Share-0.03-1.2%-0.01-0.5%-0.14-6.7%0.010.5%0.063.0%
Usd Price Per Share3.46-1.89-2.00-4.83-2.67-
Price to Earnings Ratio-13.95--12.83--3.28--18.94--10.03-
Price-to-Total Gains Ratio-138.19-253.96--18.97--106.87--60.28-
Price to Book Ratio4.36-2.33-1.78-4.55-4.33-
Price-to-Total Gains Ratio-138.19-253.96--18.97--106.87--60.28-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.03
Number of shares492
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.01
Usd Total Gains Per Share-0.010.01
Gains per Quarter (492 shares)-5.204.69
Gains per Year (492 shares)-20.8118.75
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
14-24-314159
27-49-5282928
311-73-73134447
414-98-94175866
518-122-115217385
622-146-1362587104
725-171-15729102123
829-195-17834116142
932-220-19938131161
1036-244-22042146180

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%2.038.00.05.0%4.077.02.04.8%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%12.027.01.030.0%21.058.04.025.3%
Dividend per Share1.00.03.025.0%4.00.08.033.3%4.00.016.020.0%6.00.034.015.0%7.00.076.08.4%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%7.013.00.035.0%14.025.01.035.0%23.056.04.027.7%

Fundamentals of Nephros

About Nephros Inc

Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Fundamental data was last updated by Penke on 2024-04-11 15:45:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Nephros Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Nephros earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Nephros to the Medical Instruments & Supplies industry mean.
  • A Net Profit Margin of -20.1% means that $-0.20 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nephros Inc:

  • The MRQ is -20.1%. The company is making a huge loss. -2
  • The TTM is -11.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-20.1%TTM-11.4%-8.7%
TTM-11.4%YOY-75.6%+64.3%
TTM-11.4%5Y-45.2%+33.8%
5Y-45.2%10Y-152.0%+106.8%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.1%6.3%-26.4%
TTM-11.4%6.5%-17.9%
YOY-75.6%8.2%-83.8%
5Y-45.2%7.3%-52.5%
10Y-152.0%7.6%-159.6%
1.1.2. Return on Assets

Shows how efficient Nephros is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nephros to the Medical Instruments & Supplies industry mean.
  • -5.5% Return on Assets means that Nephros generated $-0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nephros Inc:

  • The MRQ is -5.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.5%TTM-3.5%-2.0%
TTM-3.5%YOY-14.5%+10.9%
TTM-3.5%5Y-7.7%+4.2%
5Y-7.7%10Y-20.6%+12.9%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.5%1.3%-6.8%
TTM-3.5%1.4%-4.9%
YOY-14.5%2.0%-16.5%
5Y-7.7%2.2%-9.9%
10Y-20.6%2.0%-22.6%
1.1.3. Return on Equity

Shows how efficient Nephros is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nephros to the Medical Instruments & Supplies industry mean.
  • -7.8% Return on Equity means Nephros generated $-0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nephros Inc:

  • The MRQ is -7.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.8%TTM-4.6%-3.2%
TTM-4.6%YOY-25.0%+20.4%
TTM-4.6%5Y-15.4%+10.8%
5Y-15.4%10Y-36.5%+21.1%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.8%2.6%-10.4%
TTM-4.6%2.9%-7.5%
YOY-25.0%3.9%-28.9%
5Y-15.4%3.9%-19.3%
10Y-36.5%4.0%-40.5%

1.2. Operating Efficiency of Nephros Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Nephros is operating .

  • Measures how much profit Nephros makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nephros to the Medical Instruments & Supplies industry mean.
  • An Operating Margin of -19.9% means the company generated $-0.20  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nephros Inc:

  • The MRQ is -19.9%. The company is operating very inefficient. -2
  • The TTM is -11.3%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-19.9%TTM-11.3%-8.6%
TTM-11.3%YOY-52.8%+41.5%
TTM-11.3%5Y-40.4%+29.1%
5Y-40.4%10Y-81.6%+41.2%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.9%7.9%-27.8%
TTM-11.3%7.6%-18.9%
YOY-52.8%11.4%-64.2%
5Y-40.4%10.2%-50.6%
10Y-81.6%10.7%-92.3%
1.2.2. Operating Ratio

Measures how efficient Nephros is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • An Operation Ratio of 1.20 means that the operating costs are $1.20 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Nephros Inc:

  • The MRQ is 1.199. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.115. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.199TTM1.115+0.085
TTM1.115YOY1.528-0.413
TTM1.1155Y1.400-0.286
5Y1.40010Y1.823-0.423
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1991.133+0.066
TTM1.1151.124-0.009
YOY1.5281.082+0.446
5Y1.4001.101+0.299
10Y1.8231.056+0.767

1.3. Liquidity of Nephros Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Nephros is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A Current Ratio of 3.98 means the company has $3.98 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Nephros Inc:

  • The MRQ is 3.978. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.281. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.978TTM5.281-1.304
TTM5.281YOY6.028-0.747
TTM5.2815Y5.622-0.340
5Y5.62210Y3.813+1.809
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9782.320+1.658
TTM5.2812.382+2.899
YOY6.0282.575+3.453
5Y5.6222.627+2.995
10Y3.8132.623+1.190
1.3.2. Quick Ratio

Measures if Nephros is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nephros to the Medical Instruments & Supplies industry mean.
  • A Quick Ratio of 2.75 means the company can pay off $2.75 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nephros Inc:

  • The MRQ is 2.746. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.718. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.746TTM3.718-0.971
TTM3.718YOY3.513+0.205
TTM3.7185Y3.614+0.104
5Y3.61410Y2.552+1.062
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7461.111+1.635
TTM3.7181.137+2.581
YOY3.5131.286+2.227
5Y3.6141.423+2.191
10Y2.5521.521+1.031

1.4. Solvency of Nephros Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Nephros assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nephros to Medical Instruments & Supplies industry mean.
  • A Debt to Asset Ratio of 0.30 means that Nephros assets are financed with 29.5% credit (debt) and the remaining percentage (100% - 29.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Nephros Inc:

  • The MRQ is 0.295. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.215. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.295TTM0.215+0.081
TTM0.215YOY0.160+0.055
TTM0.2155Y0.233-0.019
5Y0.23310Y0.582-0.349
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2950.351-0.056
TTM0.2150.357-0.142
YOY0.1600.357-0.197
5Y0.2330.359-0.126
10Y0.5820.371+0.211
1.4.2. Debt to Equity Ratio

Measures if Nephros is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nephros to the Medical Instruments & Supplies industry mean.
  • A Debt to Equity ratio of 41.9% means that company has $0.42 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nephros Inc:

  • The MRQ is 0.419. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.279. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.419TTM0.279+0.141
TTM0.279YOY0.278+0.000
TTM0.2795Y0.499-0.220
5Y0.49910Y1.249-0.751
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4190.541-0.122
TTM0.2790.559-0.280
YOY0.2780.545-0.267
5Y0.4990.610-0.111
10Y1.2490.669+0.580

2. Market Valuation of Nephros Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Nephros generates.

  • Above 15 is considered overpriced but always compare Nephros to the Medical Instruments & Supplies industry mean.
  • A PE ratio of -13.95 means the investor is paying $-13.95 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nephros Inc:

  • The EOD is -8.182. Based on the earnings, the company is expensive. -2
  • The MRQ is -13.945. Based on the earnings, the company is expensive. -2
  • The TTM is -12.832. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.182MRQ-13.945+5.764
MRQ-13.945TTM-12.832-1.113
TTM-12.832YOY-3.283-9.550
TTM-12.8325Y-18.943+6.111
5Y-18.94310Y-10.026-8.918
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD-8.18214.638-22.820
MRQ-13.94517.745-31.690
TTM-12.83218.883-31.715
YOY-3.28322.272-25.555
5Y-18.94320.830-39.773
10Y-10.02625.069-35.095
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Nephros Inc:

  • The EOD is -17.150. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -29.232. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 1.502. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-17.150MRQ-29.232+12.081
MRQ-29.232TTM1.502-30.733
TTM1.502YOY-19.117+20.618
TTM1.5025Y-30.683+32.185
5Y-30.68310Y-16.446-14.237
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD-17.15010.196-27.346
MRQ-29.23210.068-39.300
TTM1.5021.5020.000
YOY-19.1173.822-22.939
5Y-30.6837.817-38.500
10Y-16.4460.759-17.205
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Nephros is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A PB ratio of 4.36 means the investor is paying $4.36 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Nephros Inc:

  • The EOD is 2.561. Based on the equity, the company is underpriced. +1
  • The MRQ is 4.365. Based on the equity, the company is fair priced.
  • The TTM is 2.333. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.561MRQ4.365-1.804
MRQ4.365TTM2.333+2.032
TTM2.333YOY1.782+0.550
TTM2.3335Y4.551-2.219
5Y4.55110Y4.332+0.219
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD2.5612.427+0.134
MRQ4.3652.782+1.583
TTM2.3332.828-0.495
YOY1.7823.290-1.508
5Y4.5513.530+1.021
10Y4.3324.227+0.105
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Nephros Inc.

3.1. Institutions holding Nephros Inc

Institutions are holding 40.288% of the shares of Nephros Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Wexford Capital LP34.92832.73273682724-4714-0.1278
2023-12-31Bard Associates Inc1.77660.246118731812790.6875
2023-12-31Vanguard Group Inc1.624801713105980.3503
2023-12-31Geode Capital Management, LLC0.673707103700
2023-12-31HighTower Advisors, LLC0.53790.00035671000
2023-12-31Blair William & Co0.34380.00043624900
2023-12-31Morgan Stanley - Brokerage Accounts0.320303377418482120.8606
2023-12-31Elkhorn Partners Limited Partnership0.30260.076131900-13441-29.6443
2023-12-31State Street Corporation0.148901569800
2023-12-31Mesirow Fin Investmt Mgmt Intl Equity0.14590.001915383153830
2023-12-31Susquehanna International Group, LLP0.1118011784117840
2023-12-31Granite Investment Partners, LLC0.10640.001511220112200
2023-12-31BlackRock Inc0.03920413100
2023-12-31Tower Research Capital LLC0.02370.0001249422681003.5398
2023-12-31Wells Fargo & Co0.000707245.8824
2023-12-31UBS Group AG0.000101100
2023-12-31JPMorgan Chase & Co0.0001010225
2023-12-31Bank of America Corp0.00010880
2023-09-30Renaissance Technologies Corp000-13705-100
2023-09-30Advisor Group Holdings, Inc.000-5-100
Total 41.08493.05914331833+29163+0.7%

3.2. Funds holding Nephros Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv0.9813010346000
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.67640.00027132213041.8624
2024-02-29Fidelity Extended Market Index0.4630.000448821-237-0.4831
2024-02-29Fidelity Series Total Market Index0.13380.00011410600
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0670.0004706700
2023-12-31Northern Trust Extended Eq Market Idx0.0670.0004706700
2024-03-31State St US Extended Mkt Indx NL Cl C0.03320.0004350000
2023-12-31SSgA U.S. Extended Market Index Class I0.03320.0005350000
2024-02-29Fidelity Total Market Index0.03270344600
2024-02-29Fidelity Nasdaq Composite Index0.02930.0001308500
2024-03-29Dimensional US Equity ETF0.02690.0001283400
2024-02-29DFA US Core Equity 1 I0.01850195100
2024-03-29Dimensional US Core Equity 2 ETF0.01440151700
2024-02-29DFA US Core Equity 2 I0.01130119400
2024-02-29Spartan Total Market Index Pool E0.01110116700
2023-12-31Northern Trust Wilshire 50000.0110.0001115800
2023-12-31NT US Market Cap Idx Fd - L0.0110.0001115800
2024-02-29Dimensional US Core Equity USD Acc0.010.0021105410540
2023-12-31SSgA U.S. Total Market Index Strategy0.00960.00011010-23-2.2265
2024-02-29Spartan Extended Market Index Pool E0.00340.0001360237192.6829
Total 2.64410.0051278777+2335+0.8%

3.3. Insider Transactions

Insiders are holding 11.962% of the shares of Nephros Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-12-07Robert R Jr. BanksBUY180002.2
2023-08-14Robert R Jr. BanksBUY991.5

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Nephros Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.025-0.012-50%-0.139+456%0.007-438%0.021-218%
Book Value Per Share--0.7930.819-3%1.051-25%1.040-24%0.558+42%
Current Ratio--3.9785.281-25%6.028-34%5.622-29%3.813+4%
Debt To Asset Ratio--0.2950.215+38%0.160+85%0.233+27%0.582-49%
Debt To Equity Ratio--0.4190.279+50%0.278+51%0.499-16%1.249-66%
Dividend Per Share---0.002-100%0.003-100%0.002-100%0.039-100%
Eps---0.062-0.040-35%-0.175+182%-0.101+63%-0.093+49%
Free Cash Flow Per Share---0.0300.018-266%-0.077+159%-0.062+110%-0.060+102%
Free Cash Flow To Equity Per Share---0.0300.014-311%-0.076+154%0.001-2433%0.021-243%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--5.329--------
Intrinsic Value_10Y_min---1.307--------
Intrinsic Value_1Y_max---0.028--------
Intrinsic Value_1Y_min---0.222--------
Intrinsic Value_3Y_max--0.344--------
Intrinsic Value_3Y_min---0.593--------
Intrinsic Value_5Y_max--1.232--------
Intrinsic Value_5Y_min---0.878--------
Market Cap21403711.000-70%36481202.00019927329.408+83%21080019.410+73%50934136.931-28%28128904.608+30%
Net Profit Margin---0.201-0.114-43%-0.756+276%-0.452+125%-1.520+656%
Operating Margin---0.199-0.113-43%-0.528+165%-0.404+103%-0.816+309%
Operating Ratio--1.1991.115+8%1.528-22%1.400-14%1.823-34%
Pb Ratio2.561-70%4.3652.333+87%1.782+145%4.551-4%4.332+1%
Pe Ratio-8.182+41%-13.945-12.832-8%-3.283-76%-18.943+36%-10.026-28%
Price Per Share2.030-70%3.4601.890+83%1.999+73%4.831-28%2.668+30%
Price To Free Cash Flow Ratio-17.150+41%-29.2321.502-2047%-19.117-35%-30.683+5%-16.446-44%
Price To Total Gains Ratio-81.075+41%-138.186253.958-154%-18.966-86%-106.867-23%-60.285-56%
Quick Ratio--2.7463.718-26%3.513-22%3.614-24%2.552+8%
Return On Assets---0.055-0.035-36%-0.145+163%-0.077+40%-0.206+273%
Return On Equity---0.078-0.046-41%-0.250+220%-0.154+97%-0.365+366%
Total Gains Per Share---0.025-0.011-58%-0.136+443%0.010-363%0.060-141%
Usd Book Value--8358000.0008632250.000-3%11086250.000-25%10961350.000-24%5879275.000+42%
Usd Book Value Change Per Share---0.025-0.012-50%-0.139+456%0.007-438%0.021-218%
Usd Book Value Per Share--0.7930.819-3%1.051-25%1.040-24%0.558+42%
Usd Dividend Per Share---0.002-100%0.003-100%0.002-100%0.039-100%
Usd Eps---0.062-0.040-35%-0.175+182%-0.101+63%-0.093+49%
Usd Free Cash Flow---312000.000188000.000-266%-808500.000+159%-653900.000+110%-630275.000+102%
Usd Free Cash Flow Per Share---0.0300.018-266%-0.077+159%-0.062+110%-0.060+102%
Usd Free Cash Flow To Equity Per Share---0.0300.014-311%-0.076+154%0.001-2433%0.021-243%
Usd Market Cap21403711.000-70%36481202.00019927329.408+83%21080019.410+73%50934136.931-28%28128904.608+30%
Usd Price Per Share2.030-70%3.4601.890+83%1.999+73%4.831-28%2.668+30%
Usd Profit---654000.000-394000.000-40%-1831000.000+180%-1059650.000+62%-1109725.000+70%
Usd Revenue--3254000.0003559500.000-9%2509500.000+30%2678750.000+21%1721925.000+89%
Usd Total Gains Per Share---0.025-0.011-58%-0.136+443%0.010-363%0.060-141%
 EOD+3 -5MRQTTM+5 -30YOY+23 -125Y+15 -2010Y+24 -11

4.2. Fundamental Score

Let's check the fundamental score of Nephros Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.182
Price to Book Ratio (EOD)Between0-12.561
Net Profit Margin (MRQ)Greater than0-0.201
Operating Margin (MRQ)Greater than0-0.199
Quick Ratio (MRQ)Greater than12.746
Current Ratio (MRQ)Greater than13.978
Debt to Asset Ratio (MRQ)Less than10.295
Debt to Equity Ratio (MRQ)Less than10.419
Return on Equity (MRQ)Greater than0.15-0.078
Return on Assets (MRQ)Greater than0.05-0.055
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Nephros Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.012
Ma 20Greater thanMa 502.145
Ma 50Greater thanMa 1002.682
Ma 100Greater thanMa 2002.906
OpenGreater thanClose2.040
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets11,861
Total Liabilities3,503
Total Stockholder Equity8,358
 As reported
Total Liabilities 3,503
Total Stockholder Equity+ 8,358
Total Assets = 11,861

Assets

Total Assets11,861
Total Current Assets8,405
Long-term Assets3,456
Total Current Assets
Cash And Cash Equivalents 4,307
Net Receivables 1,496
Inventory 2,470
Other Current Assets 132
Total Current Assets  (as reported)8,405
Total Current Assets  (calculated)8,405
+/-0
Long-term Assets
Property Plant Equipment 1,959
Goodwill 759
Intangible Assets 652
Long-term Assets Other 86
Long-term Assets  (as reported)3,456
Long-term Assets  (calculated)3,456
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,113
Long-term Liabilities1,390
Total Stockholder Equity8,358
Total Current Liabilities
Short-term Debt 446
Accounts payable 873
Other Current Liabilities 794
Total Current Liabilities  (as reported)2,113
Total Current Liabilities  (calculated)2,113
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,390
Long-term Liabilities  (as reported)1,390
Long-term Liabilities  (calculated)1,390
+/-0
Total Stockholder Equity
Common Stock10
Retained Earnings -144,406
Other Stockholders Equity 152,754
Total Stockholder Equity (as reported)8,358
Total Stockholder Equity (calculated)8,358
+/-0
Other
Capital Stock10
Cash and Short Term Investments 4,307
Common Stock Shares Outstanding 10,544
Liabilities and Stockholders Equity 11,861
Net Debt -2,471
Net Invested Capital 8,358
Net Working Capital 6,292
Property Plant and Equipment Gross 2,921
Short Long Term Debt Total 1,836



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302003-12-312002-12-312002-06-302001-12-31
> Total Assets 
395
148
1,280
5,034
6,265
15,421
12,207
12,863
11,084
9,438
7,825
7,825
8,883
6,205
5,167
5,167
2,380
14,191
10,085
8,761
7,353
5,328
4,036
3,172
2,340
3,279
2,652
2,652
1,942
1,682
1,590
3,649
2,794
2,885
3,994
3,599
4,349
3,956
3,528
2,737
2,882
2,556
2,889
3,059
2,352
3,105
3,369
3,369
3,391
4,305
3,970
3,427
3,995
3,010
2,678
3,279
2,841
2,824
4,983
4,632
6,845
9,404
10,558
10,138
12,014
11,554
11,629
18,294
16,649
15,242
18,510
17,936
17,991
17,820
17,650
15,528
14,953
11,205
10,999
10,927
10,386
10,919
11,861
11,86110,91910,38610,92710,99911,20514,95315,52817,65017,82017,99117,93618,51015,24216,64918,29411,62911,55412,01410,13810,5589,4046,8454,6324,9832,8242,8413,2792,6783,0103,9953,4273,9704,3053,3913,3693,3693,1052,3523,0592,8892,5562,8822,7373,5283,9564,3493,5993,9942,8852,7943,6491,5901,6821,9422,6522,6523,2792,3403,1724,0365,3287,3538,76110,08514,1912,3805,1675,1676,2058,8837,8257,8259,43811,08412,86312,20715,4216,2655,0341,280148395
   > Total Current Assets 
0
0
0
0
5,364
14,581
11,012
11,627
9,932
8,243
6,664
6,664
7,856
5,146
4,233
4,233
1,606
13,474
9,296
3,724
6,694
4,747
3,603
2,823
2,051
3,040
2,421
2,421
1,783
1,546
1,482
3,564
2,733
2,848
3,199
3,584
2,235
1,777
1,403
667
870
600
988
1,212
560
1,367
1,684
1,684
1,812
2,779
2,464
1,873
2,454
1,532
1,264
1,928
1,553
1,609
3,809
3,514
5,771
8,376
8,173
7,172
8,437
8,117
8,299
14,809
13,070
11,755
15,154
14,667
14,840
13,621
13,634
11,657
11,122
8,988
8,261
8,324
7,914
8,506
8,405
8,4058,5067,9148,3248,2618,98811,12211,65713,63413,62114,84014,66715,15411,75513,07014,8098,2998,1178,4377,1728,1738,3765,7713,5143,8091,6091,5531,9281,2641,5322,4541,8732,4642,7791,8121,6841,6841,3675601,2129886008706671,4031,7772,2353,5843,1992,8482,7333,5641,4821,5461,7832,4212,4213,0402,0512,8233,6034,7476,6943,7249,29613,4741,6064,2334,2335,1467,8566,6646,6648,2439,93211,62711,01214,5815,3640000
       Cash And Cash Equivalents 
0
0
0
0
3,698
9,439
3,719
4,315
2,817
829
747
747
1,691
51
253
253
530
6,513
3,449
2,505
1,404
3,745
2,306
1,651
890
1,795
1,004
1,004
344
421
240
2,247
1,713
2,117
1,669
2,174
987
366
47
243
298
168
579
473
225
1,047
1,284
1,284
1,037
1,813
1,248
701
1,602
807
275
803
301
150
2,194
1,819
3,484
5,322
4,581
3,608
4,318
3,855
4,166
8,962
7,046
5,155
8,249
8,163
8,278
7,350
6,973
5,421
4,179
3,940
3,634
3,836
4,060
4,622
4,307
4,3074,6224,0603,8363,6343,9404,1795,4216,9737,3508,2788,1638,2495,1557,0468,9624,1663,8554,3183,6084,5815,3223,4841,8192,1941503018032758071,6027011,2481,8131,0371,2841,2841,047225473579168298243473669872,1741,6692,1171,7132,2472404213441,0041,0041,7958901,6512,3063,7451,4042,5053,4496,513530253253511,6917477478292,8174,3153,7199,4393,6980000
       Short-term Investments 
0
0
0
0
0
4,000
5,996
5,995
5,997
5,999
4,500
4,500
5,000
3,655
2,800
2,800
0
4,000
4,700
0
4,100
7
7
7
0
0
0
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22
26
22
27
21
15
20
20
26
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000002620201521272226220000000000000000000000070007774,10004,7004,00002,8002,8003,6555,0004,5004,5005,9995,9975,9955,9964,00000000
       Net Receivables 
0
0
0
0
24
24
175
221
220
230
244
244
375
181
228
228
10
114
419
405
278
322
404
436
320
525
629
629
652
449
326
574
587
203
1,170
1,040
890
1,070
935
140
355
104
122
475
113
179
110
110
295
216
397
569
346
311
388
582
584
751
836
704
886
1,532
1,452
1,249
1,539
1,894
1,045
1,597
870
901
1,364
1,718
1,382
1,555
1,641
1,293
2,128
1,374
1,286
1,963
1,576
1,443
1,496
1,4961,4431,5761,9631,2861,3742,1281,2931,6411,5551,3821,7181,3649018701,5971,0451,8941,5391,2491,4521,5328867048367515845823883113465693972162951101101791134751221043551409351,0708901,0401,1702035875743264496526296295253204364043222784054191141022822818137524424423022022117524240000
       Inventory 
0
0
0
202
103
337
653
587
528
469
815
815
475
903
512
512
634
560
336
355
422
337
724
589
767
607
653
653
697
608
726
624
334
396
247
240
268
293
312
189
147
291
162
192
163
108
186
186
419
665
591
476
413
341
479
401
603
581
674
928
1,352
1,459
1,864
2,040
2,314
2,128
2,562
3,649
4,769
5,385
5,304
4,679
5,087
4,649
4,795
4,679
4,664
3,488
3,153
2,348
2,126
2,268
2,470
2,4702,2682,1262,3483,1533,4884,6644,6794,7954,6495,0874,6795,3045,3854,7693,6492,5622,1282,3142,0401,8641,4591,352928674581603401479341413476591665419186186108163192162291147189312293268240247396334624726608697653653607767589724337422355336560634512512903475815815469528587653337103202000
   > Long-term Assets 
0
0
0
0
902
839
1,196
1,235
1,153
1,195
1,161
1,161
1,027
1,059
0
934
774
717
789
5,037
659
581
433
349
289
239
0
231
159
136
108
85
61
37
795
15
2,114
2,179
2,125
2,070
2,012
1,956
1,901
1,847
1,792
1,738
1,685
1,685
1,579
1,526
1,506
1,554
1,541
1,478
1,414
1,351
1,288
1,215
1,174
1,118
1,074
1,028
2,385
2,966
3,577
3,437
3,330
3,485
3,579
3,487
3,356
3,269
3,151
4,199
4,016
3,871
3,831
2,217
2,738
2,603
2,472
2,413
3,456
3,4562,4132,4722,6032,7382,2173,8313,8714,0164,1993,1513,2693,3563,4873,5793,4853,3303,4373,5772,9662,3851,0281,0741,1181,1741,2151,2881,3511,4141,4781,5411,5541,5061,5261,5791,6851,6851,7381,7921,8471,9011,9562,0122,0702,1252,1792,1141579537618510813615923102392893494335816595,03778971777493401,0591,0271,1611,1611,1951,1531,2351,1968399020000
       Property Plant Equipment 
103
76
77
488
898
836
1,192
1,230
1,149
1,191
1,143
1,143
1,009
1,041
911
911
751
694
762
724
632
554
412
328
269
218
210
210
138
115
108
85
61
37
17
15
21
19
16
14
12
9
7
5
3
1
1
1
0
0
12
41
84
77
70
63
56
49
52
35
28
20
91
684
1,339
1,250
1,187
1,329
1,467
1,419
1,332
1,289
1,200
1,196
1,096
1,028
1,076
532
1,100
1,004
922
838
1,959
1,9598389221,0041,1005321,0761,0281,0961,1961,2001,2891,3321,4191,4671,3291,1871,2501,33968491202835524956637077844112001113579121416192115173761851081151382102102182693284125546327247626947519119111,0411,0091,1431,1431,1911,1491,2301,1928368984887776103
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
748
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
759
75975975975975975975975975975975975975975975975975975975975974800000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,093
2,160
2,109
2,056
2,000
1,947
1,894
1,842
1,789
1,737
1,684
1,684
1,579
1,526
1,494
1,494
1,368
1,315
1,262
1,210
1,157
1,105
1,072
1,038
1,005
971
1,528
1,484
1,440
1,396
1,352
1,308
1,264
1,220
1,176
1,132
1,088
2,142
2,072
2,000
1,929
868
825
780
737
693
652
6526937377808258681,9292,0002,0722,1421,0881,1321,1761,2201,2641,3081,3521,3961,4401,4841,5289711,0051,0381,0721,1051,1571,2101,2621,3151,3681,4941,4941,5261,5791,6841,6841,7371,7891,8421,8941,9472,0002,0562,1092,1602,093000000000000000000000000000000000000
       Long-term Assets Other 
0
0
0
0
4
4
4
5
4
4
18
18
18
18
23
23
23
23
27
27
27
27
21
21
20
21
21
21
21
21
0
0
0
0
778
0
2,093
2,160
2,109
2,056
2,000
1,947
1,894
1,842
1,789
1,737
1,684
1,631
1,579
1,526
1,494
1,442
1,389
1,336
21
21
21
11
11
11
41
37
18
39
39
32
32
89
89
89
89
89
104
102
89
84
67
58
54
60
54
123
86
86123546054586784891021048989898989323239391837411111112121211,3361,3891,4421,4941,5261,5791,6311,6841,7371,7891,8421,8941,9472,0002,0562,1092,1602,0930778000021212121212021212727272723232323181818184454440000
> Total Liabilities 
2,037
1,104
3,389
3,166
15,819
4,014
2,557
2,522
2,748
2,761
2,445
2,445
6,979
2,441
7,263
7,263
7,354
19,834
1,329
1,532
2,539
1,922
1,502
1,411
928
867
694
694
867
884
1,455
867
566
1,032
2,573
2,565
3,452
3,633
4,123
4,433
2,041
2,126
3,499
2,293
2,136
3,491
9,050
9,050
9,320
1,513
1,306
1,434
2,322
1,793
2,011
1,905
2,058
2,559
3,033
2,734
2,347
5,337
3,760
4,534
5,208
4,832
3,940
4,658
4,373
3,802
2,937
2,399
3,000
2,490
2,901
2,126
2,472
1,624
2,118
2,033
1,731
2,297
3,503
3,5032,2971,7312,0332,1181,6242,4722,1262,9012,4903,0002,3992,9373,8024,3734,6583,9404,8325,2084,5343,7605,3372,3472,7343,0332,5592,0581,9052,0111,7932,3221,4341,3061,5139,3209,0509,0503,4912,1362,2933,4992,1262,0414,4334,1233,6333,4522,5652,5731,0325668671,4558848676946948679281,4111,5021,9222,5391,5321,32919,8347,3547,2637,2632,4416,9792,4452,4452,7612,7482,5222,5574,01415,8193,1663,3891,1042,037
   > Total Current Liabilities 
2,037
1,104
3,389
3,166
3,657
4,014
2,557
2,522
2,748
2,761
1,831
1,831
1,357
2,019
1,691
1,691
1,807
1,521
1,329
1,532
2,539
1,922
1,502
1,411
928
867
694
694
867
884
1,455
867
566
1,032
2,573
1,343
2,442
2,752
3,416
3,902
1,689
1,950
3,499
2,293
1,684
3,057
1,247
1,247
1,364
1,148
959
1,104
1,218
684
895
780
923
1,412
1,871
1,731
1,396
1,440
2,654
3,110
3,292
3,116
2,428
3,108
2,765
2,379
1,325
1,408
2,170
1,823
2,390
1,748
2,111
1,421
1,412
1,415
1,197
1,828
2,113
2,1131,8281,1971,4151,4121,4212,1111,7482,3901,8232,1701,4081,3252,3792,7653,1082,4283,1163,2923,1102,6541,4401,3961,7311,8711,4129237808956841,2181,1049591,1481,3641,2471,2473,0571,6842,2933,4991,9501,6893,9023,4162,7522,4421,3432,5731,0325668671,4558848676946948679281,4111,5021,9222,5391,5321,3291,5211,8071,6911,6912,0191,3571,8311,8312,7612,7482,5222,5574,0143,6573,1663,3891,1042,037
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
296
296
388
388
380
380
417
372
781
0
0
0
0
0
0
0
0
0
0
0
500
0
0
0
0
0
0
0
-386
1,300
0
0
1,358
0
0
1,604
0
0
0
0
0
0
0
0
0
0
892
563
711
334
340
354
1,186
1,296
1,447
1,440
1,033
1,022
813
890
561
579
594
609
612
588
515
370
387
313
323
311
446
4463113233133873705155886126095945795618908131,0221,0331,4401,4471,2961,18635434033471156389200000000001,604001,358001,300-3860000000500000000000007813724173803803883882962960000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
892
1,485
1,665
184
187
191
195
1,105
1,224
1,189
771
710
498
564
229
233
238
243
248
253
210
141
71
0
0
0
0
0000711412102532482432382332295644987107711,1891,2241,1051951911871841,6651,48589200000000000000000000000000000000000000000000000000000000
       Accounts payable 
1,891
693
946
1,416
2,028
1,203
630
549
710
756
766
766
560
843
568
568
770
392
488
610
1,125
856
986
1,013
723
616
455
455
585
584
441
651
464
427
284
512
360
584
2,388
1,387
786
1,065
1,073
1,033
1,030
908
1,177
835
988
924
652
744
838
444
585
361
513
436
872
1,069
679
562
836
1,030
915
690
959
1,575
1,316
887
423
495
1,100
641
1,334
897
1,411
779
740
719
302
805
873
8738053027197407791,4118971,3346411,1004954238871,3161,5759596909151,0308365626791,0698724365133615854448387446529249888351,1779081,0301,0331,0731,0657861,3872,3885843605122844274646514415845854554556167231,0139868561,1256104883927705685688435607667667567105496301,2032,0281,4169466931,891
       Other Current Liabilities 
41
61
1,833
1,500
1,590
2,804
1,863
1,932
2,018
2,005
769
769
409
788
743
743
620
757
60
922
1,414
1,066
516
398
205
251
239
239
182
233
481
199
102
105
195
132
1,408
1,464
707
507
200
183
365
194
233
300
70
342
306
154
237
290
310
170
240
349
340
343
218
328
377
524
236
272
329
271
300
203
187
6
673
680
476
573
444
263
185
272
285
383
572
712
794
7947125723832852721852634445734766806736187203300271329272236524377328218343340349240170310290237154306342703002331943651832005077071,4641,4081321951051021994812331822392392512053985161,0661,414922607576207437437884097697692,0052,0181,9321,8632,8041,5901,5001,8336141
   > Long-term Liabilities 
0
0
0
0
12,161
0
0
0
0
1,500
614
614
5,622
422
0
5,572
5,547
18,313
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,222
1,010
881
707
531
352
176
0
0
452
434
7,803
7,803
7,956
365
347
330
1,104
1,109
1,116
1,125
1,135
1,147
1,162
1,003
951
3,897
1,106
1,424
1,916
1,716
1,512
1,550
1,608
1,423
1,612
991
830
667
511
378
361
203
706
618
534
469
1,390
1,3904695346187062033613785116678309911,6121,4231,6081,5501,5121,7161,9161,4241,1063,8979511,0031,1621,1471,1351,1251,1161,1091,1043303473657,9567,8037,803434452001763525317078811,0101,2220000000000000000018,3135,5475,57204225,6226146141,500000012,1610000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
791
814
0
0
0
0
0
0
0
0
843
787
730
682
623
562
692
569
846
299
232
0
0
0
0
0
0
0
0
0
0
0000000000232299846569692562623682730787843000000008147910000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
103
183
259
5,547
1,097
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,222
1,010
881
707
531
352
176
0
0
452
434
7,803
6,777
7,956
365
347
330
313
295
278
261
243
225
208
0
0
0
263
231
163
78
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000781632312630002082252432612782953133303473657,9566,7777,803434452001763525317078811,0101,222000000000000000001,0975,5472591831030000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
452
434
417
400
382
365
347
330
313
295
278
261
243
225
208
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000020822524326127829531333034736538240041743445200000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
1,868
-9,553
11,407
9,651
10,341
8,336
6,678
5,379
5,379
1,904
3,764
0
-2,096
-4,974
-5,643
8,756
7,229
4,814
3,406
2,534
1,761
1,412
2,412
1,958
1,958
1,075
798
135
2,782
2,228
1,853
1,421
1,034
897
323
-595
-1,696
841
430
-610
766
216
-386
-5,681
-5,681
-5,929
2,792
2,664
1,993
1,673
1,217
667
1,374
783
265
1,950
1,898
4,498
4,067
3,798
2,604
3,803
3,713
4,675
10,596
9,230
8,388
12,522
12,484
11,937
12,276
11,695
10,160
9,221
6,302
5,592
8,894
8,655
8,622
8,358
8,3588,6228,6558,8945,5926,3029,22110,16011,69512,27611,93712,48412,5228,3889,23010,5964,6753,7133,8032,6043,7984,0674,4981,8981,9502657831,3746671,2171,6731,9932,6642,792-5,929-5,681-5,681-386216766-610430841-1,696-5953238971,0341,4211,8532,2282,7821357981,0751,9581,9582,4121,4121,7612,5343,4064,8147,2298,756-5,643-4,974-2,09603,7641,9045,3795,3796,6788,33610,3419,65111,407-9,5531,868000
   Retained Earnings -144,406-143,752-143,570-143,137-142,831-141,983-138,829-137,692-135,725-134,683-133,521-132,395-131,858-131,100-130,087-128,430-127,332-127,188-126,444-125,502-124,153-123,489-122,939-122,257-121,106-122,395-121,763-120,977-120,285-119,630-118,924-118,089-117,253-116,318-115,737-114,165-114,165-103,348-102,642-101,988-101,228-100,053-99,442-98,772-97,530-96,432-95,579-94,825-94,268-93,630-93,217-92,615-91,908-91,243-90,869-89,975-89,975-89,492-89,097-88,684-87,949-87,042-85,695-83,252-81,612-59,918-58,456-55,256-55,256-49,290-51,096-47,243-47,243-45,948-44,200-42,168-41,775-39,758-30,8930000
   Accumulated Other Comprehensive Income 
0
0
0
0
-2,464
-2,308
-2,327
-2,244
-2,216
-2,116
-875
-2,239
-47
-102
-1,181
12
40
78
110
191
187
93
70
21
62
88
-2,097
76
-34
42
22
57
70
75
49
93
39
56
76
76
74
74
74
73
72
73
-733
72
71
72
71
72
71
72
67
68
75
76
77
80
74
73
71
68
70
63
65
64
65
69
74
68
70
66
64
61
0
0
0
0
0
0
0
00000006164667068746965646563706871737480777675686772717271727172-7337372737474747676563993497570572242-3476-2,0978862217093187191110784012-1,181-102-47-2,239-875-2,116-2,216-2,244-2,327-2,308-2,4640000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
95,365
95,398
0
0
0
0
0
0
0
0
100,526
102,656
102,761
102,864
108,382
108,409
109,705
118,993
119,797
119,961
120,477
120,726
0
0
0
0
0
0
0
0
127,816
127,974
130,169
130,830
131,934
138,953
139,243
139,410
144,296
144,801
145,378
0
0
0
0
0
0
0
0
0
0
0000000000145,378144,801144,296139,410139,243138,953131,934130,830130,169127,974127,81600000000120,726120,477119,961119,797118,993109,705108,409108,382102,864102,761102,656100,5260000000095,39895,36500000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue14,238
Cost of Revenue-6,047
Gross Profit8,1918,191
 
Operating Income (+$)
Gross Profit8,191
Operating Expense-9,784
Operating Income-1,593-1,593
 
Operating Expense (+$)
Research Development873
Selling General Administrative8,287
Selling And Marketing Expenses0
Operating Expense9,7849,160
 
Net Interest Income (+$)
Interest Income43
Interest Expense-2
Other Finance Cost-2
Net Interest Income39
 
Pretax Income (+$)
Operating Income-1,593
Net Interest Income39
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-1,575-1,611
EBIT - interestExpense = -1,595
-1,575
-1,573
Interest Expense2
Earnings Before Interest and Taxes (EBIT)-1,593-1,573
Earnings Before Interest and Taxes (EBITDA)-1,379
 
After tax Income (+$)
Income Before Tax-1,575
Tax Provision-0
Net Income From Continuing Ops-1,640-1,575
Net Income-1,575
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses15,831
Total Other Income/Expenses Net18-39
 

Technical Analysis of Nephros
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nephros. The general trend of Nephros is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nephros's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Nephros Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 2.05 < 2.05 < 2.06.

The bearish price targets are: 1.88 > 1.6 > 1.4701.

Tweet this
Nephros Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Nephros Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Nephros Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Nephros Inc. The current macd is -0.16942509.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nephros price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Nephros. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Nephros price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Nephros Inc Daily Moving Average Convergence/Divergence (MACD) ChartNephros Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Nephros Inc. The current adx is 32.75.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Nephros shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Nephros Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Nephros Inc. The current sar is 1.97.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Nephros Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Nephros Inc. The current rsi is 33.01. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Nephros Inc Daily Relative Strength Index (RSI) ChartNephros Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Nephros Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nephros price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Nephros Inc Daily Stochastic Oscillator ChartNephros Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Nephros Inc. The current cci is -71.29722798.

Nephros Inc Daily Commodity Channel Index (CCI) ChartNephros Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Nephros Inc. The current cmo is -29.91300353.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Nephros Inc Daily Chande Momentum Oscillator (CMO) ChartNephros Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Nephros Inc. The current willr is -82.77841561.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Nephros Inc Daily Williams %R ChartNephros Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Nephros Inc.

Nephros Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Nephros Inc. The current atr is 0.14820307.

Nephros Inc Daily Average True Range (ATR) ChartNephros Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Nephros Inc. The current obv is 1,999,580.

Nephros Inc Daily On-Balance Volume (OBV) ChartNephros Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Nephros Inc. The current mfi is 20.45.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Nephros Inc Daily Money Flow Index (MFI) ChartNephros Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Nephros Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-01WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Nephros Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Nephros Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.012
Ma 20Greater thanMa 502.145
Ma 50Greater thanMa 1002.682
Ma 100Greater thanMa 2002.906
OpenGreater thanClose2.040
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Nephros with someone you think should read this too:
  • Are you bullish or bearish on Nephros? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nephros? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Nephros Inc

I send you an email if I find something interesting about Nephros Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Nephros Inc.

Receive notifications about Nephros Inc in your mailbox!